SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mkilloran who wrote (12588)8/4/1998 4:35:00 PM
From: VLAD  Read Replies (3) of 23519
 
martin,

If the likes of J&J wanted to buy Vivus they now have had ample time to buy millions of shares on the open market in the 5 3/4 to 7 range.
By the time they file the SEC forms they could already own over 5 million shares. Then if they do pay Vivus over 15 bucks the actual average would be much lower. It seems to me like the fillings on Edgar are always old and not up to date but this is where you can check.

My gut feeling at this point is that since Vivus management owns 25% of the shares, they only want to negotiate a favorable deal with a domestic partner to sell MUSE. I feel that they don't care where the stock price is in the near future and they will simply wait until they show profits in Q3 and Q4. If they do well it will prove to the Street that they can thrive in the world market and the stock price will trade upwards to a reasonable level. If $1.00/share 12 months forward is proven, then as CO from PW predicts, 2o/share is very doable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News